Physician profile
Alejandro Lerma
NPI 1679892566
$8,622.30
in general payments reported to CMS, 2019-2025
40 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $1,243 · 2021: $1,933 · 2022: $1,930 · 2023: $878 · 2024: $614 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,184.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,851.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $753.16 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $733.59 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $708.45 | 2019-2023 | Xarelto |
| Allergan, INC. | $649.53 | 2019-2020 | |
| Amgen INC. | $511.32 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $466.30 | 2019-2024 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals Lp | $368.41 | 2019-2025 | Farxiga, Breztri |
| Horizon Therapeutics Plc | $242.93 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $237.57 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $230.84 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $214.60 | 2019-2023 | Lagevrio, Verquvo, Segluromet |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.13 | 2020-2024 | Xifaxan |
| Amarin Pharma, INC. | $168.42 | 2020-2022 | |
| Dexcom, INC. | $149.92 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Lerma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.